Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cc-122 + rituximab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
CC-122 + rituximab is an investigational **combination therapy** comprising avadomide (code name CC-122), a small molecule cereblon E3 ligase modulator (CELMoD), and rituximab, a CD20-directed monoclonal antibody. Preclinical and early clinical data indicate this combination exerts **synergistic antitumor effects**: avadomide acts by modulating the cereblon E3 ubiquitin ligase to induce tumor cell apoptosis and immunomodulation, while rituximab targets CD20 on B cells for antibody-dependent cell-mediated cytotoxicity. This combination has been studied in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), showing tolerability and preliminary antitumor activity in these difficult-to-treat populations[3][4][5][1].
- Other names
- avadomide + rituximab
02
Targets
IKZF1 (Ikaros family zinc finger protein 1)CRBN (Cereblon)IKZF3 (Zinc finger protein Aiolos)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on cc-122 + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cc-122 + rituximab.